Status:
COMPLETED
Oral Misoprostol Versus Intravenous Oxytocin in Preventing Blood Loss After Non-scheduled Cesarean Section
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Postpartum Hemorrhage
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
Postpartum hemorrhage (PPH) ranks among the leading causes of maternal morbidity and mortality, both in developed and developing countries. With this trial, we sought to determine the effectiveness o...
Detailed Description
Postpartum hemorrhage (PPH) is still among the leading causes of maternal morbidity and mortality. The incidence of PPH is reduced by active management of the third stage of labor which includes the u...
Eligibility Criteria
Inclusion
- Non-scheduled primary or secondary Cesarean section (CS) after the 37th week of gestation
Exclusion
- Emergency CS
- Fetal distress
- Fetal malformations
- Preeclampsia and HELLP (Hemolysis-Elevated Liver enzymes-Low Platelet count syndrome)
- Hypersensitivity to prostaglandins
- Coagulopathy
- Severe systemic disorders
- An American Society of Anesthesiologists (ASA) physical status \>/= 3
- Severe asthma
- Prior myomectomy
- Maternal fever (\> 38.5 °C)
Key Trial Info
Start Date :
January 1 1999
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2002
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT00107874
Start Date
January 1 1999
End Date
February 1 2002
Last Update
April 4 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Women's University Hospital, Basel
Basel, Switzerland, 4031